Rani Therapeutics Holdings, Inc. Class A Common Stock

RANINASDAQUSD
0.86 USD
0.04 (3.96%)🟢LIVE (AS OF 10:31 AM EDT)
🟢Market: OPEN
Open?$0.89
High?$0.90
Low?$0.86
Prev. Close?$0.90
Volume?114.6K
Avg. Volume?1.0M
VWAP?$0.87
Rel. Volume?0.11x
Bid / Ask
Bid?$0.74 × 100
Ask?$0.99 × 100
Spread?$0.25
Midpoint?$0.87
Valuation & Ratios
Market Cap?101.2M
Shares Out?99.9M
Float?73.3M
Float %?75.2%
P/E Ratio?N/A
P/B Ratio?3.56
EPS?-$0.26
Dividend?0.00%
Ex-Dividend?N/A

Rani Therapeutics Holdings, Inc. Class A Common Stock (RANI) trades at $0.86 per share. The technical outlook is "Strong Sell" and the fundamental picture shows "Neutral". This is driven by a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation front, RANI trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Employees
69
Market Cap
98.4M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2021-07-30
Address
2051 RINGWOOD AVENUE
SAN JOSE, CA 95131
Phone: (408) 457-3700
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-3/3)
Medium-Term (Wave)? Bearish(-2/3)
Short-Term (Ripple)? Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
0
Momentum?
77
Short Sent.?
59
Piotroski F-Score?3/9Weak
Altman Z-Score?-1.43Distress
Confidence?48%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?10.86%High
Short Interest?8.0M
Days to Cover?8.5
Free Float73.3M
Avg Daily Volume942.7K
Settlement Date2026-05-15
Financial Health
Current Ratio?3.40Strong
Quick Ratio?3.40Strong
Cash Ratio?0.70Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A
P/B?
Peers
100
S&P
48
3.56FAIR
P/S?
Peers
100
S&P
3
31.92HIGH
P/FCF?
N/A
EV/EBITDA?
S&P
97
-2.7CHEAP
EV/Sales?
Peers
100
S&P
3
28.88HIGH
Returns & Efficiency
ROE?
S&P
3
-103.6%WEAK
ROA?
S&P
3
-56.8%WEAK
Cash Flow & Enterprise
FCF?$-17114000
Enterprise Value?$91.5M
Fundamentals ratios updated end of day